Vaxcyte Inc (US:PCVX) — Company Overview, News & Financial Data
Vaxcyte develops next-generation vaccines to prevent infectious diseases, including candidates for pneumococcal and pertussis.
About Vaxcyte Inc
Vaxcyte (NASDAQ:PCVX) is a biotech company focused on developing vaccines to prevent a wide range of infectious diseases. Drawing on cutting-edge research and technology, Vaxcyte is dedicated to engineering next-generation vaccines that promise higher efficacy, safety, and accessibility. The company's portfolio encompasses several projects, including lead candidates aimed at combating pneumococcal and pertussis diseases. With a strong commitment to public health, Vaxcyte's objective is to significantly reduce the global burden of infectious diseases through innovative vaccination solutions. Their approach combines pioneering science with a strategic vision to address unmet medical needs and protect populations around the world.
Snapshot
Operations
Products and/or services of Vaxcyte Inc
- VAX-24, a 24-valent pneumococcal conjugate vaccine targeting a broad range of pneumococcal serotypes for adult and pediatric use.
- VAX-A1, a novel protein-based vaccine for Group A Strep, designed to prevent infections caused by the most common strains.
- VAX-PG, a protein-conjugate vaccine aimed at preventing infections caused by the bacterial pathogen Group B Streptococcus, targeting pregnant women for the protection of newborns.
- Prevnar 20™, a partnership project for an advanced pneumococcal vaccine offering broad coverage against pneumonia and invasive disease in adults.
- SCV-07, an immune-modulating compound for the treatment of viral and bacterial infections, including hepatitis and certain cancers.
- VAX-XP, a pneumococcal conjugate vaccine with an expanded coverage for serotypes not included in current vaccines, aimed at enhancing pneumococcal disease prevention.
Vaxcyte Inc executive team
- Mr. Grant E. Pickering M.B.A.Co-Founder, CEO & Director
- Mr. Andrew L. Guggenhime M.B.A.President & CFO
- Mr. James Wassil M.B.A., M.S.Executive VP & COO
- Mr. Mikhail Eydelman J.D.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
- Dr. Jeff Fairman Ph.D.Co-Founder & VP of Research
- Ms. Whitney JonesChief People Officer
- Ms. Janet GraesserSenior Vice President of Corporate Affairs
- Mr. Harp Dhaliwal M.B.A.Chief Technical Operations Officer
- Sam IkiSenior Vice President of Project Management
- Ms. Elvia CowanSenior Vice President of Finance